Last reviewed · How we verify
APPA
APPA, marketed by AKL Research and Development, is a therapeutic agent with a unique mechanism of action targeting a specific biological pathway. The key composition patent for APPA is set to expire in 2028, providing a clear timeline for potential generic competition. Given the lack of detailed revenue and trial results, the primary risk remains the uncertainty around APPA's market performance and competitive landscape.
At a glance
| Generic name | APPA |
|---|---|
| Sponsor | AKL Research and Development |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Testing APPA-1 in Healthy Subjects and Osteoarthritis Patients (PHASE1)
- Acute Effects of Reformer, Cadillac, and Chair Pilates Appa-ratuses on Cardiac Autonomic Modulation and Flexibility (NA)
- Evaluating a Virtual Mentoring Program Plus Mental Health Videos for Teens (NA)
- A Trial of APPA in the Treatment of Knee Osteoarthritis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- APPA CI brief — competitive landscape report
- APPA updates RSS · CI watch RSS
- AKL Research and Development portfolio CI